LPI receives final FDA approval for generic version of Levaquin tablets

Jun 23 2011NewsGuard 100/100 Score

Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of Ortho McNeil's Levaquin® (levofloxacin) tablets.  Commercial shipment of the product has commenced.

Lupin's levofloxacin 250 mg, 500 mg and 750 mg tablets are the AB-rated generic equivalent of Levaquin, a synthetic broad spectrum antibacterial agent used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.   Levaquin tablets had annual sales of approximately $1.6 billion for the twelve months ended March 2011, based on IMS Health sales data.

Source:

Lupin Pharmaceuticals, Inc.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: , , , , ,

Comments (0)

Suggested Reading

High ultra-processed food consumption tied to rising BMI and fat mass in young children
Living in food deserts during early childhood raises long-term obesity risk
Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)
Study reveals key brain cells help resist food temptations in favor of exercise
Scientists map food microbes and their gut microbiome impact
A novel approach to photosynthetic production of high-value compounds
Reassessing the Health Star Rating: New study highlights need for ultra-processed food adjustments
SNAP emergency allotments: Reducing food insecurity in children

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New evidence connects ultra-processed foods to rising diabetes rates